Why Did One Of The World's Biggest Generic Drug Makers Exit China?
2/4/2014 8:20:07 AM
The week of JP Morgan’s January 2014 healthcare conference in San Francisco, Actavis, one of the world’s largest generic pharmaceutical companies, made a splash by emphasizing its emerging market strategy, just not the way most investors anticipated. Where most pharmaceutical companies have elevated the market opportunity in China as key to their revenue growth and profitability, Actavis made clear it views the risks in China as well beyond the potential benefits. In a much quoted interview at the JP Morgan event, Actavis’ CEO Paul Bisaro stated “If we’re going to allocate capital, we’re going to do so where we can get the most amount of return for the least amount of risk. And China is just too risky.”
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by